Talking to Your Child's
Doctor About CAPS

If you think your child might have Cryopyrin-Associated Periodic Syndromes (CAPS), you can start by having a conversation with a doctor. If the doctor suspects that your child might have CAPS, he or she may refer your child to a pediatric rheumatologist.

Before a pediatric rheumatologist can accurately diagnose CAPS, your child will need to complete a physical examination and the doctor will need a complete medical history, including:

How long, how often, and when your child has had rash, eye irritations, painful joints and/or muscles, headache, and fatigue
Whether these symptoms affect your child's normal activity level
Whether there are any other possible causes of symptoms, including an injury or another illness

Record your child's CAPS symptoms and medications

Recording your child's CAPS symptoms and medications

Keeping track of your child's CAPS symptoms and medications, and sharing this information with the doctor, will help him or her determine whether your child's CAPS symptoms have changed over time.

Download the symptom tracker

Keeping track of your child's CAPS symptoms and medications, and sharing this information with the doctor, will help him or her determine whether your child's CAPS symptoms have changed over time.

Download the symptom tracker

Things to Consider

If you feel overwhelmed when meeting with your child's doctor, consider bringing someone with you who can listen and take notes if necessary

Answer the doctor's questions honestly and directly

Feel free to talk about your emotions, stress level, or discomfort if these things are affecting you or your family

If your child is diagnosed with CAPS, including FCAS or MWS, talk to his or her doctor about ILARIS^®, learn what you can, and ask if ILARIS may be right for your child.

Next: Finding Support

More

Less

IMPORTANT SAFETY INFORMATION

ILARIS can cause serious side effects, including increased risk of serious infections. ILARIS can lower the ability of your immune system to fight infections. Your healthcare provider should:

test you for tuberculosis (TB) before you receive ILARIS.
monitor you closely for symptoms of TB during treatment with ILARIS.
check you for symptoms of any type of infection before, during, and after treatment with ILARIS.

Tell your healthcare provider right away if you have any symptoms of an infection such as fever, sweats or chills, cough, flu-like symptoms, weight loss, shortness of breath, blood in your phlegm, sores on your body, warm or painful areas on your body, diarrhea or stomach pain, or feeling very tired.

You should not receive ILARIS if you are allergic to canakinumab or any of the ingredients in ILARIS.

Before receiving ILARIS, tell your healthcare provider about all your medical conditions, including if you:

think you have or are being treated for an active infection.
have symptoms of infection.
have a history of infections that keep coming back.
have a history of low white blood cells.
have or have had HIV, Hepatitis B, or Hepatitis C.
are scheduled to receive any immunizations (vaccines). You should not get 'live vaccines' if you are receiving ILARIS.
are pregnant or planning to become pregnant. It is not known if ILARIS will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while receiving ILARIS
received canakinumab while you were pregnant. It is important that you tell your baby's healthcare provider before any vaccinations are given to your baby within 4-12 months after you received your last dose of canakinumab before giving birth
are breastfeeding or planning to breastfeed. It is not known if ILARIS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive ILARIS

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:

medicines that affect the immune system.
medicines called interleukin-1 (IL-1) blocking agents such as Kineret^® (anakinra) or Arcalyst^® (rilonacept).
medicines called Tumor Necrosis Factor (TNF) inhibitors such as Enbrel^® (etanercept), Humira^® (adalimumab), Remicade^® (infliximab), Simponi^® (golimumab), or Cimzia^® (certolizumab pegol).
medicines that affect enzyme metabolism.

Ask you healthcare provider for a list of these medicines if you are not sure.

ILARIS can cause serious side effects including:

serious infections.
decreased ability of the body to fight infections (immunosuppression). For people treated with medicines that cause immunosuppression like ILARIS, the chances of getting cancer may increase
allergic reactions. Allergic reactions can happen while receiving ILARIS. Call your healthcare provider right away if you have any of these symptoms of an allergic reaction: difficulty breathing or swallowing, nausea, dizziness or feeling faint, rash, itching or hives, palpitations (feels like your heart is racing), or low blood pressure
risk of infection with live vaccines. You should not get live vaccines if you are receiving ILARIS. Tell your healthcare provider if you are scheduled to receive any vaccines

The most common side effects of ILARIS when used for the treatment of CAPS include: cold symptoms, diarrhea, flu (influenza), runny nose, headache, cough, body aches, nausea, vomiting, and diarrhea (gastroenteritis), feeling like you are spinning (vertigo), weight gain, injection site reactions (such as redness, swelling, warmth, or itching), and nausea.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.

APPROVED USE

ILARIS^® (canakinumab) is a prescription medicine injected by your healthcare provider just below the skin (subcutaneous) used to treat adults and children aged 4 years and older who have auto-inflammatory diseases called Cryopyrin-Associated Periodic Syndromes (CAPS), including:

Familial Cold Autoinflammatory Syndrome (FCAS)
Muckle-Wells Syndrome (MWS)

It is not known if ILARIS is safe and effective when used to treat CAPS in children under 4 years of age.

All trademarks and registered trademarks are the property of their respective owners.

Talking to Your Child's Doctor About CAPS

Recording your child's CAPS symptoms and medications

Things to Consider

Things to Consider

Leaving Novartis

Talking to Your Child's
Doctor About CAPS